Nine month report January-September 2000

Nine month report January - September 2000: Continued good growth momentum but lower margins * Total revenues increased by 14% (9%*) to SEK 16,102 M. Operating earnings EBITDA was SEK 3,044 M corresponding to a margin of 18.9%. Earnings per share decreased by 17% to SEK 0.78 and cash earnings per share rose by 13% to SEK 5.85. Earnings per share including non-recurring items increased by 56% to SEK 3.66. * Good third quarter growth, +18% (+9%*), but margins lower than previous period, mainly due to higher cost levels affecting the US clinics opera- tions. * Continued strong expansion, +20% (+12%*), for Gambro Healthcare - especially in Europe. * Sales increased by 7% (7%*), for Gambro Renal Products, with a good third quarter, +11% (8%*). * Further good development for blood component technology, Gambro BCT. Revenues increased by 14% (7%*), with a significant improvement in the third quarter, +17% (+11%*). * Good progress and accelerating investments in the Pathogen Eradication Technology project. * Brad Nutter, President Gambro Healthcare, to leave Gambro. *) currency adjusted For further information please contact: Bengt Modéer, Senior Vice President, Corporate Communications, +46-8-613 65 00, +46-70-513 65 33 Lars Granlöf, Senior Vice President, CFO, +46-8-613 65 00 Cindy Lyman or Kerry Schneider, Citigate Dewe Rogerson, New York , tel. +1-212-688 6840 Gambro's financial information is also available on the Internet: www.gambro.com NINE MONTH REPORT JANUARY - SEPTEMBER 2000 For the Group, the third quarter 2000 included a continued growth of 18% (9%*). Margins were lower than previous quarter mainly due to a drug price increase, the elimination of a separate drug reimbursement and increased labor costs affecting the US clinics operations. Also currency effects have had a negative impact on the Group margins. The PET development project has made good progress and been supported by accelerated invest- ments. Operating margin (EBITDA) for the Group was 17.6%. Gambro Healthcare has expanded by 23% (11%*) including an expansion in Europe by 59%. The sales momentum in Gambro Renal Products has continued, especially on markets outside Europe. Revenues increased by 11% (8%*). For Gambro BCT revenues were up 17% (11%*). In total, the first nine months 2000 for the Group have included a revenue growth of 14% (9%*). This includes an expansion in Gambro Healthcare with 20% (12%*). Strategically the pace of US clinics acquisitions has been reduced towards the end of the period. Gambro Renal Products had a continued sales development with revenues growing by 7% (7%*) with a positive development in Europe, strong growth outside Europe as well as for internal sales which are up with more than 40%. For Gambro BCT revenues increased by 14% (7%*) with a strong development at the end of the period. The PET project has had a promising development and has been supported by higher investments. For the Group, margins during the period have been negatively affected by the higher cost level in Gambro Healthcare, currency effects as well as by the increased R&D investments in the PET projects. Operating margin (EBITDA) for the Group was 18.9%. *) currency adjusted ------------------------------------------------------------ This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/10/26/20001026BIT00200/bit0001.doc The full report http://www.bit.se/bitonline/2000/10/26/20001026BIT00200/bit0002.pdf The full report